Protara Therapeutics, Inc.
NASDAQ:TARABiotechnology
-$0.05 today
- Market cap
- $144.07M
- Beta
- 1.45
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$1.48
Volume 1.15M
Average 0.73M
TARA Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Protara Therapeutics, Inc.NASDAQ: TARA
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q1 FY2026 depreciation & amortization of $90K rose 8.4% year over year, behind the +11.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 3.2% from the prior quarter. Over 3 fiscal years it compounded at +13.4% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +8.4% toward the trailing-twelve-month pace of +11.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 362K USD
- Year-over-year change
- +9.0%
- 4-year CAGR
- +32.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 362K | +9.0% |
| FY2024 | 2024-12-31 | 332K | -2.6% |
| FY2023 | 2023-12-31 | 341K | +37.5% |
| FY2022 | 2022-12-31 | 248K | +112.0% |
| FY2021 | 2021-12-31 | 117K | — |
Depreciation & Amortization vs competitors
How TARA compares with its peers on the latest reported figures
- TARA's LTM Mar 2026 depreciation & amortization of $369K is the 7th highest of the 10 companies compared; the peer median is $1.88M.
- Its year-over-year change of +11.1% is the 2nd highest of 9, against a peer median of -4.0%.
- Over three fiscal years its annual growth of +13.4% compares with a peer median of +8.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $23.01M | -1.6% | +6.0% | 79.6% | |
| LTM Mar 2026 | $8.57M | +6.1% | -1.0% | 11.0% | |
| LTM Mar 2026 | $6.56M | -25.2% | -14.4% | 19.0% | |
| LTM Mar 2026 | $1.88M | -43.4% | +65.8% | 3.4% | |
| LTM Mar 2026 | $1.88M | +27.6% | +13.5% | 13.0% | |
| LTM Mar 2026 | $1.67M | -6.4% | +8.9% | 10.0% | |
| LTM Mar 2026 | $369K | +11.1% | +13.4% | — | |
| LTM Mar 2026 | $334K | +5.4% | +13.8% | 1.0% | |
| LTM Mar 2026 | $50.29K | — | — | — | |
| LTM Sep 2026 | $0 | -100.0% | — | — | |
| Peer median (excluding TARA) | $1.88M | -4.0% | +8.9% | 11.0% | |
Competitors are the stored peer set for TARA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 341K | 0 | 362K |
| Gross Profit | 0 | 0 | (341K) | 0 | (362K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 21.09M | 16.81M | 24.79M | 31.7M | 42.63M |
| Selling, General & Admin | 26.4M | 20.74M | 18.62M | 17.45M | 21.92M |
| Operating Expenses | 47.49M | 67.06M | 43.27M | 49.15M | 64.19M |
| Depreciation & Amortization | 117K | 248K | 341K | 332K | 362K |
| EBITDA | (45.4M) | (64.57M) | (40.08M) | (44.26M) | (57.08M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (47.49M) | (67.06M) | (43.61M) | (49.15M) | (64.55M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 237K | 1.11M | 2.73M | 4.14M | 6.33M |
| Interest Expense | 1.74M | 1.14M | 0 | 0 | 0 |
| Other Income / Expenses | 237K | 1.11M | 3.19M | 4.56M | 7.11M |
| Income Before Tax | (47.25M) | (65.95M) | (40.42M) | (44.6M) | (57.44M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (47.25M) | (65.95M) | (40.42M) | (44.6M) | (57.44M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (4.20) | (5.86) | (3.57) | (2.17) | (1.34) |
| EPS (Diluted) | (4.20) | (5.86) | (3.57) | (2.17) | (1.34) |
| Weighted Avg Shares | 11.23M | 11.26M | 11.33M | 20.59M | 42.84M |
| Weighted Avg Shares (Diluted) | 11.23M | 11.26M | 11.33M | 20.59M | 42.84M |
Protara Therapeutics, Inc.
NASDAQ:TARA
Intrinsic Alpha fair value
Locked
Current Price
$2.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.